Blocking Interleukin-33 Alleviates the Joint Inflammation and Inhibits the Development of Collagen-Induced Arthritis in Mice
Copyright © 2020 Yan Li et al..
Rheumatoid arthritis (RA) is considered a systemic chronic inflammatory joint disease characterized by chronic synovitis and cartilage and bone destruction. Interleukin-33 (IL-33) is a proinflammatory cytokine which is highly expressed in the synovium of RA patients and the joints of mice with collagen-induced arthritis (CIA) and exacerbates CIA in mice. However, the role of the IL-33-neutralizing antibody in the murine model of CIA remains unclear. In the present study, CIA mice were given intraperitoneally with polyclonal rabbit anti-murine IL-33 antibody (anti-IL-33) or normal rabbit IgG control after the first signs of arthritis. Administration of anti-IL-33 after the onset of disease significantly reduced the severity of CIA and joint damage compared with controls treated with normal rabbit IgG. Anti-IL-33 treatment also significantly decreased the serum levels of interferon-γ(IFN-γ),IL-6, IL-12, IL-33, and tumor necrosis factor-α (TNF-α). Moreover, anti-IL-33 treatment significantly downregulated the production of IFN-γ, IL-6, IL-12, IL-33, and TNF-α in ex vivo-stimulated spleen cells. Together, our results indicate that the IL-33-neutralizing antibody may provide a therapeutic strategy for RA by inhibiting the release of proinflammatory cytokines.
Medienart: |
E-Artikel |
---|
Erscheinungsjahr: |
2020 |
---|---|
Erschienen: |
2020 |
Enthalten in: |
Zur Gesamtaufnahme - volume:2020 |
---|---|
Enthalten in: |
Journal of immunology research - 2020(2020) vom: 27., Seite 4297354 |
Sprache: |
Englisch |
---|
Beteiligte Personen: |
Li, Yan [VerfasserIn] |
---|
Links: |
---|
Themen: |
9007-34-5 |
---|
Anmerkungen: |
Date Completed 20.09.2021 Date Revised 20.09.2021 published: Electronic-eCollection Citation Status MEDLINE |
---|
doi: |
10.1155/2020/4297354 |
---|
funding: |
|
---|---|
Förderinstitution / Projekttitel: |
|
PPN (Katalog-ID): |
NLM320523888 |
---|
LEADER | 01000naa a22002652 4500 | ||
---|---|---|---|
001 | NLM320523888 | ||
003 | DE-627 | ||
005 | 20231225173751.0 | ||
007 | cr uuu---uuuuu | ||
008 | 231225s2020 xx |||||o 00| ||eng c | ||
024 | 7 | |a 10.1155/2020/4297354 |2 doi | |
028 | 5 | 2 | |a pubmed24n1068.xml |
035 | |a (DE-627)NLM320523888 | ||
035 | |a (NLM)33490289 | ||
040 | |a DE-627 |b ger |c DE-627 |e rakwb | ||
041 | |a eng | ||
100 | 1 | |a Li, Yan |e verfasserin |4 aut | |
245 | 1 | 0 | |a Blocking Interleukin-33 Alleviates the Joint Inflammation and Inhibits the Development of Collagen-Induced Arthritis in Mice |
264 | 1 | |c 2020 | |
336 | |a Text |b txt |2 rdacontent | ||
337 | |a ƒaComputermedien |b c |2 rdamedia | ||
338 | |a ƒa Online-Ressource |b cr |2 rdacarrier | ||
500 | |a Date Completed 20.09.2021 | ||
500 | |a Date Revised 20.09.2021 | ||
500 | |a published: Electronic-eCollection | ||
500 | |a Citation Status MEDLINE | ||
520 | |a Copyright © 2020 Yan Li et al. | ||
520 | |a Rheumatoid arthritis (RA) is considered a systemic chronic inflammatory joint disease characterized by chronic synovitis and cartilage and bone destruction. Interleukin-33 (IL-33) is a proinflammatory cytokine which is highly expressed in the synovium of RA patients and the joints of mice with collagen-induced arthritis (CIA) and exacerbates CIA in mice. However, the role of the IL-33-neutralizing antibody in the murine model of CIA remains unclear. In the present study, CIA mice were given intraperitoneally with polyclonal rabbit anti-murine IL-33 antibody (anti-IL-33) or normal rabbit IgG control after the first signs of arthritis. Administration of anti-IL-33 after the onset of disease significantly reduced the severity of CIA and joint damage compared with controls treated with normal rabbit IgG. Anti-IL-33 treatment also significantly decreased the serum levels of interferon-γ(IFN-γ),IL-6, IL-12, IL-33, and tumor necrosis factor-α (TNF-α). Moreover, anti-IL-33 treatment significantly downregulated the production of IFN-γ, IL-6, IL-12, IL-33, and TNF-α in ex vivo-stimulated spleen cells. Together, our results indicate that the IL-33-neutralizing antibody may provide a therapeutic strategy for RA by inhibiting the release of proinflammatory cytokines | ||
650 | 4 | |a Journal Article | |
650 | 7 | |a Antibodies, Neutralizing |2 NLM | |
650 | 7 | |a Cytokines |2 NLM | |
650 | 7 | |a Il33 protein, mouse |2 NLM | |
650 | 7 | |a Interleukin-33 |2 NLM | |
650 | 7 | |a Collagen |2 NLM | |
650 | 7 | |a 9007-34-5 |2 NLM | |
700 | 1 | |a Fu, Yeqin |e verfasserin |4 aut | |
700 | 1 | |a Chen, Huan |e verfasserin |4 aut | |
700 | 1 | |a Liu, Xiaojin |e verfasserin |4 aut | |
700 | 1 | |a Li, Mingcai |e verfasserin |4 aut | |
773 | 0 | 8 | |i Enthalten in |t Journal of immunology research |d 2014 |g 2020(2020) vom: 27., Seite 4297354 |w (DE-627)NLM237451581 |x 2314-7156 |7 nnns |
773 | 1 | 8 | |g volume:2020 |g year:2020 |g day:27 |g pages:4297354 |
856 | 4 | 0 | |u http://dx.doi.org/10.1155/2020/4297354 |3 Volltext |
912 | |a GBV_USEFLAG_A | ||
912 | |a GBV_NLM | ||
951 | |a AR | ||
952 | |d 2020 |j 2020 |b 27 |h 4297354 |